地舒单抗停药后的临床经验
该回顾性队列研究纳入66例经平均6.7年地舒单抗治疗后停药的患者,按ECTS立场声明建议序贯使用唑来膦酸。首次唑来膦酸后12个月腰椎和全髋骨密度分别下降2.5%和1.9%,12至24个月各部位骨密度无显著变化,研究期间无骨折发生。
要点
- 地舒单抗停药后按ECTS建议序贯唑来膦酸,平均3次输注可限制12和24个月时的骨量丢失。
- 首次唑来膦酸后12个月腰椎和全髋骨密度分别下降2.5±4.2%和1.9±2.5%(n=44),股骨颈无显著变化。
- 30%和22%的患者在首次和第二次唑来膦酸输注后出现流感样症状。
核心结论
- 遵循ECTS立场声明的建议,平均3次唑来膦酸输注限制了地舒单抗停药后12和24个月时的骨量丢失,从而保留了地舒单抗治疗期间获得的大部分骨密度。
- 唑来膦酸后流感样症状频繁发生是一项挑战,作者认为在地舒单抗停药后接受唑来膦酸治疗的患者中应考虑针对急性期反应的常规预防。
研究设计与样本
- 回顾性队列研究,基于因停用地舒单抗而转诊的患者的病历资料。
- 共纳入66名女性和男性,地舒单抗平均治疗时长为6.7±2.7年(均值±标准差)。
- 在末次地舒单抗注射后6个月给予唑来膦酸,此后在第3、6、12和24个月时,若血清I型胶原C端交联(CTX)升高至0.5 μg/l以上,或第12和24个月时骨密度下降(髋部≥5%,脊柱≥3%),则再次给予唑来膦酸。
主要发现
- 首次唑来膦酸治疗后12个月,腰椎骨密度下降2.5±4.2%,全髋骨密度下降1.9±2.5%(n=44)(所有p≤0.001)。
- 股骨颈骨密度无显著变化(0.0±5.1)(p>0.05)。
- 从第12个月到第24个月,任何部位的骨密度均无显著变化(所有p>0.05)。
- 30%和22%的患者分别在首次和第二次唑来膦酸输注后出现流感样症状。
- 研究期间无骨折发生。
临床怎么用
- 作者认为,在地舒单抗停药后接受唑来膦酸治疗的患者中应考虑针对急性期反应的常规预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In patients receiving long-term treatment with denosumab, denosumab discontinuation via sequential treatment with zoledronate, resulted in a minor decrease in bone mass density (BMD) of 0-2.5% within the first year and stabile BMD in the second year, thus showing that repeated treatments with zoledronate limit the loss of BMD, when discontinuing denosumab. PURPOSE: Discontinuing denosumab (DMAb) rapidly decreases bone mineral density (BMD) and increases the risk of multiple vertebral fractures. We wanted to examine if the recommendation stated in the ECTS position paper on DMAb discontinuation can prevent the bone loss in a clinical setting. METHODS: We conducted a retrospective cohort study based on medical records of patients referred for DMAb discontinuation. We administered zoledronate (ZOL) 6 months after the last DMAb injection and 3, 6, 12, and 24 months thereafter if p-C-terminal collagen crosslinks (CTX) increased above 0.5 μg/l or BMD decreased (≥ 5% at the hip, ≥ 3% at the spine) at months 12 and 24. RESULTS: We included 66 women and men discontinuing DMAb after a mean treatment duration of 6.7 ± 2.7 (mean ± SD) years. BMD decreased 12 months after the initial ZOL treatment by 2.5 ± 4.2% and 1.9 ± 2.5% at the LS and TH, respectively (n = 44) (p ≤ 0.001 for all). There was no significant change in FNBMD (0.0 ± 5.1) (p > 0.05). No significant change in BMD was seen from month 12 to month 24 at any site (p > 0.05 for all). Thirty percent and twenty-two percent of patients experienced flu-like symptoms after the first and second ZOL infusion. No fractures occurred during the study period. CONCLUSION: Adhering to the recommendation in the ECTS position statement, a mean of 3 infusions of ZOL limited the bone loss 12 and 24 months after DMAb discontinuation, thereby preserving most of the BMD gained during DMAb treatment. The frequent occurrence of flu-like symptoms after ZOL proves to be a challenge, showing that routine prophylaxis against acute phase responses should be considered in patients treated with ZOL after discontinuing DMAb.
引用
- Laursen N, Sølling AS, Harsløf T, et al. Clinical experience with denosumab discontinuation. Osteoporos Int. 2025. PMID: 39777495. doi:10.1007/s00198-024-07351-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。